Short Interest in BioLineRx Ltd. (NASDAQ:BLRX) Declines By 90.2%

BioLineRx Ltd. (NASDAQ:BLRX) was the recipient of a significant decrease in short interest in January. As of January 31st, there was short interest totalling 122,900 shares, a decrease of 90.2% from the January 15th total of 1,260,000 shares. Approximately 3.3% of the company’s stock are sold short. Based on an average daily volume of 208,100 shares, the days-to-cover ratio is presently 0.6 days.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on BLRX shares. StockNews.com started coverage on shares of BioLineRx in a research report on Tuesday, February 4th. They issued a “hold” rating on the stock. HC Wainwright reduced their target price on BioLineRx from $840.00 to $360.00 and set a “buy” rating for the company in a report on Monday, November 25th.

BioLineRx Stock Performance

Shares of BLRX traded up $0.13 during mid-day trading on Wednesday, reaching $3.52. 73,976 shares of the company’s stock were exchanged, compared to its average volume of 433,111. The business’s fifty day simple moving average is $6.61 and its 200-day simple moving average is $16.60. The stock has a market capitalization of $7.04 million, a PE ratio of -0.40 and a beta of 1.41. BioLineRx has a 52-week low of $3.24 and a 52-week high of $57.60. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.52 and a quick ratio of 1.37.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($2.80) EPS for the quarter, beating analysts’ consensus estimates of ($3.20) by $0.40. BioLineRx had a negative net margin of 90.57% and a negative return on equity of 163.37%. On average, equities research analysts expect that BioLineRx will post -5.8 earnings per share for the current year.

Hedge Funds Weigh In On BioLineRx

An institutional investor recently raised its position in BioLineRx stock. Atria Investments Inc grew its stake in BioLineRx Ltd. (NASDAQ:BLRX) by 27.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 133,974 shares of the biotechnology company’s stock after purchasing an additional 29,193 shares during the period. Atria Investments Inc owned approximately 0.17% of BioLineRx worth $72,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.